LGALS9 and acute myeloid leukemia: In a panel of patient-derived AML cells in co-culture with MS5, Gal-9 dose-dependently reduced viability by ~90% for CD34+ AML and ~75% for CD34− AML, respectively (Fig. 2F, G).